Researchers enrolled 602 patients at elevated risk for post-ERCP pancreatitis in the study. They received either a single dose of the nonsteroidal antiinflammatory drug or placebo immediately after ERCP.
Post-ERCP pancreatitis developed in 27 of 295 patients (9.2 percent) in the indomethacin group and in 52 of 307 patients (16.9 percent) in the placebo group. Moderate-to-severe pancreatitis developed in 13 patients (4.4 percent) in the indomethacin group and in 27 patients (8.8 percent) in the placebo group.
Related Articles on New Research:
Study: Colorectal Cancer Screenings Increase When Patients Given Options
Study: Patients With GI Disorders May Receive Significant Doses of Diagnostic Radiation
Study: Adult Irritable Bowel Syndrome Linked to Childhood Trauma
